ONM-501 is under clinical development by OncoNano Medicine and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ONM-501’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ONM-501 overview

ONM-501 is under development for the treatment of triple negative breast cancer, lymphomas and solid tumor. It acts by targeting stimulator of interferon genes (STING). It is administered by intratumor route. It is being developed based on OncoNano’s OMNI platform.

OncoNano Medicine overview

OncoNano Medicine (OncoNano) is biotechnology company that develops pH-activated compounds that digitalize and exploit the variability of pH in disease. The company pipeline includes ON501. The company utilizes pH variability, a biomarker to detect and treat diseased tissue. OncoNano’s ON-BOARD micelle platform carries a wide variety of payloads for systemic administration to the tumor microenvironment and OMNI platform deliver therapeutic payloads and directly activates a ubiquitous immune signaling molecule for cancer immunotherapy. It develops products in the therapeutic areas of cancer, alzheimer’s and metabolic disorders. OncoNano is headquartered in Southlake, Texas, the US.

For a complete picture of ONM-501’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.